FDA Advisory Panel Rejects Vioxx Successor(Page 3) Earlier this week, the FDA staff had concluded that if safer alternatives were available, U.S. regulators should not approve new painkillers in the same class as Vioxx. The March 21 memorandum was released Tuesday, ahead of the FDA advisory panel meeting. Since pulling Vioxx from the market, Merck has faced more than 10,000 lawsuits from former patients and their families. More information For more information on heart disease and cox-2 inhibitors, visit the American Heart Association Association. Related Links
advertisement
| ||
What's HOTGet our free newsletter
PR Newswire |
 |
The drkoop.com URL and web site are not associated with C. Everett Koop, M.D., former Surgeon General of the United States.
By using this service, you accept our Terms of Use. Please read them. The consumer health information on drkoop.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2004-2008. The HealthCentral Network, Inc. All rights reserved.